PALO ALTO, Calif. & SECAUCUS, N.J., September 24, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest ...
Guardant Health and Quest Diagnostics previously announced a multi-year collaboration to offer the FDA-approved Shield blood-based colorectal cancer screening test to Quest's large U.S. provider ...
Guardant Health is rated a strong buy, driven by its Shield blood-based colorectal cancer screening and a transformative collaboration with Quest Diagnostics. GH’s Shield test addresses major barriers ...
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States Collaboration to enable streamlined and ...
Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Shield is the first and only blood test to receive full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results